Harrow Health (HROW) Tops Q2 EPS by 2c

Go back to Harrow Health (HROW) Tops Q2 EPS by 2c

Harrow Announces Second Quarter 2023 Financial Results

August 9, 2023 4:01 PM EDT

Second Quarter 2023 and Recent Selected Highlights:

Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in the sequential quarter. GAAP net loss of ($4.2) million. Record adjusted EBITDA of $11.0 million, an increase of 144% over $4.5 million in the prioryear quarter and an increase of 108% over $5.3 million in the sequential quarter. Completed public offering of common stock for aggregate gross proceeds of $69 million. Expanded Oaktree Loan from $100 million to $112.50 million. Acquired certain commercial rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands... More